Dual Antiplatelet Therapy

DAPT for 1 months or 12 months in patients with ACS undergoing PCI with a cobalt-chromium everolimus-eluting stent (Xience family, Abbott Vascular).

In a pooled cohort of the two STOPDAPT-2 trials, among patients who underwent PCI, switching from dual antiplatelet therapy to clopidogrel monotherapy after 1 month reduced bleeding risk compared with 12-month DAPT.

Magnetically controlled capsule endoscopy identified gastrointestinal injury in a majority patients taking antiplatelet therapies following PCI and may represent a noninvasive alternative to standard upper GI endoscopy, a speaker reported.

In a subgroup analysis of MASTER-DAPT, regardless of whether patients had a history of MI, 1-month DAPT after PCI was noninferior to 3-month or longer DAPT for ischemic events and conferred a reduction in bleeding events.

Long-term ticagrelor monotherapy after PCI lowered risk for bleeding compared with 1-year dual antiplatelet therapy followed by 1-year aspirin monotherapy in patients with ACS, but not for those with CAD.

Dual antiplatelet therapy for 1 month vs. 3 or more months in patients at high bleeding risk who had PCI with a biodegradable-polymer sirolimus-eluting stent (Ultimaster, Terumo).

Despite fewer bleeding events, 1-month dual antiplatelet therapy with clopidogrel failed to prove noninferiority vs. 12-month DAPT after PCI and stent implantation for ACS, according to a presenter.

In patients at high bleeding risk, dual antiplatelet therapy for 1 month after PCI lowered bleeding rates and was noninferior for ischemic events compared with 3-month DAPT, according to results of the MASTER DAPT trial.

At 10 years, patients with three-vessel or left main disease who underwent PCI or CABG were more likely to survive if they were taking optimal medical therapy at 5 years, researchers reported.

DAPT for 3 months or 12 months after PCI with an everolimus-eluting stent (Synergy, Boston Scientific).